MX2013008225A - Composicion farmaceutica que comprende agonistas de opioide y antagonista secuestrado. - Google Patents

Composicion farmaceutica que comprende agonistas de opioide y antagonista secuestrado.

Info

Publication number
MX2013008225A
MX2013008225A MX2013008225A MX2013008225A MX2013008225A MX 2013008225 A MX2013008225 A MX 2013008225A MX 2013008225 A MX2013008225 A MX 2013008225A MX 2013008225 A MX2013008225 A MX 2013008225A MX 2013008225 A MX2013008225 A MX 2013008225A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
opioid agonist
oxycodone
compositions
sequestered antagonist
Prior art date
Application number
MX2013008225A
Other languages
English (en)
Spanish (es)
Inventor
Edward Scott Wilson
Original Assignee
Alpharma Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpharma Pharmaceuticals Llc filed Critical Alpharma Pharmaceuticals Llc
Publication of MX2013008225A publication Critical patent/MX2013008225A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2013008225A 2011-02-02 2012-01-25 Composicion farmaceutica que comprende agonistas de opioide y antagonista secuestrado. MX2013008225A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161438882P 2011-02-02 2011-02-02
PCT/IB2012/050348 WO2012104752A1 (en) 2011-02-02 2012-01-25 Pharmaceutical composition comprising opioid agonist and sequestered antagonist

Publications (1)

Publication Number Publication Date
MX2013008225A true MX2013008225A (es) 2013-08-12

Family

ID=45607315

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008225A MX2013008225A (es) 2011-02-02 2012-01-25 Composicion farmaceutica que comprende agonistas de opioide y antagonista secuestrado.

Country Status (14)

Country Link
US (1) US20140141090A1 (enExample)
EP (1) EP2670400A1 (enExample)
JP (3) JP2014504630A (enExample)
KR (4) KR20160031038A (enExample)
CN (1) CN103415285A (enExample)
AU (3) AU2012213056A1 (enExample)
BR (1) BR112013019431A2 (enExample)
CA (1) CA2824835A1 (enExample)
IL (1) IL227770A0 (enExample)
MX (1) MX2013008225A (enExample)
RU (1) RU2013136350A (enExample)
SG (1) SG191872A1 (enExample)
WO (1) WO2012104752A1 (enExample)
ZA (1) ZA201305108B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60138706D1 (de) 2000-02-08 2009-06-25 Euro Celtique Sa Missbrauchssichere orale opioid-agonist zubereitungen
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
MX377251B (es) 2010-03-24 2025-03-07 Jazz Pharmaceuticals Inc Star Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
JP2020536892A (ja) * 2017-10-09 2020-12-17 ローズ ファーマシューティカルズ エル．ピー． 医薬レジネート組成物、それを作製する方法、およびその使用
AU2019383389A1 (en) 2018-11-19 2021-05-06 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
WO2020178695A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
KR20230071228A (ko) 2021-11-16 2023-05-23 김명진 가상공간에 사용자가 마시는 주류를 적용하기 위한 방법 및 장치
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4293539A (en) 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
GB9104854D0 (en) 1991-03-07 1991-04-17 Reckitt & Colmann Prod Ltd Sustained release compositions
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
DE60138706D1 (de) 2000-02-08 2009-06-25 Euro Celtique Sa Missbrauchssichere orale opioid-agonist zubereitungen
CN2423892Y (zh) * 2000-04-30 2001-03-21 尹为民 分隔式药物胶囊
WO2002092059A1 (en) 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
DK1414451T3 (da) * 2001-08-06 2009-08-10 Euro Celtique Sa Opioidagonistformuleringer med frigivelig og sekvenstreret antagonist
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
DE10353196A1 (de) 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix
DE10353186A1 (de) 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
EP1755556A4 (en) 2004-05-04 2009-09-30 Innophos Inc DIRECTLY COMPRESSIBLE TRICALCIUM PHOSPHATE
MX2008016372A (es) 2006-06-19 2009-05-28 Alpharma Inc Composiciones farmaceuticas.
AU2007322269A1 (en) * 2006-10-11 2008-05-29 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2224805A4 (en) * 2007-12-17 2013-10-16 Alpharma Pharmaceuticals Llc PHARMACEUTICAL COMPOSITION
CN101461809A (zh) * 2007-12-18 2009-06-24 重庆药友制药有限责任公司 一种泮托拉唑钠肠溶片及其制备方法
JP2013540807A (ja) * 2010-10-26 2013-11-07 アルファーマ ファーマシューティカルズ エルエルシー オピオイド過量投与によって誘発される呼吸抑制を減弱する製剤および方法

Also Published As

Publication number Publication date
US20140141090A1 (en) 2014-05-22
ZA201305108B (en) 2014-09-25
KR20190014577A (ko) 2019-02-12
WO2012104752A1 (en) 2012-08-09
BR112013019431A2 (pt) 2020-10-27
KR20180027641A (ko) 2018-03-14
JP2017081942A (ja) 2017-05-18
AU2016200708A1 (en) 2016-02-25
AU2012213056A1 (en) 2013-07-25
AU2017204639A1 (en) 2017-07-27
CA2824835A1 (en) 2012-08-09
JP2014504630A (ja) 2014-02-24
SG191872A1 (en) 2013-08-30
KR20130124551A (ko) 2013-11-14
RU2013136350A (ru) 2015-03-27
KR20160031038A (ko) 2016-03-21
CN103415285A (zh) 2013-11-27
JP2018109059A (ja) 2018-07-12
EP2670400A1 (en) 2013-12-11
IL227770A0 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
MX2013008225A (es) Composicion farmaceutica que comprende agonistas de opioide y antagonista secuestrado.
IL230819A0 (en) Refractory oral pharmaceutical dosage form containing an opioid agonist and an opioid antagonist
IL228506A (en) Opioid receptor ligands and pharmacy preparations containing them
IL210185A0 (en) Methods, compositions and systems for local delivery of drugs
TWI561933B (en) Resist underlayer film forming composition containing silicone having nitrogen-containing ring
IL230528B (en) An abuse-resistant pharmaceutical preparation for the treatment of opioid addiction
EP2680899A4 (en) Medicament delivery device for administration of opioid antagonists including formulations for naloxone
PL2619212T3 (pl) Analogi buprenorfiny działające agonistycznie i/lub antagonistycznie na receptory opioidowe
LT2552920T (lt) Nauji nk-3 receptoriaus selektyvūs antagonistų junginiai, farmacinė kompozicija ir būdai, skirti naudoti nk-3 receptoriaus sąlygotų sutrikimų gydymui
BRPI0919711A2 (pt) composições farmacêuticas com liberação atenuada de opióides fenólicos
WO2012032209A3 (es) Uso de un agonista de trpm8 para la elaboración de un medicamento para el tratamiento de xeroftalmia, sequedad vaginal y síndrome de la boca seca y uso de un antagonista de trpm8 para la elaboración de un medicamento pra el tratamiento de la epífora.
MX2015000114A (es) Composiciones farmaceuticas disuasivas de abuso de liberacion prolongada.
WO2009117669A3 (en) Treatment with opioid antagonists and mtor inhibitors
IL215813A0 (en) Pariticulate pharmaceutical composition with an opioid and an opioid antagonist
ZA201309359B (en) Compositions for sequential administration of opioid receptor agonists
IL233266A0 (en) Methods for the treatment and prevention of opioid-induced constipation using oral compositions of methylnaltrexone
TR201803744T4 (tr) Skleroderma tedavisinde kullanım için naltrekson içeren bileşimler.
PT2802311T (pt) Composição farmacêutica sublingual contendo um agente anti-histamínico e método para a sua preparação
AP2012006607A0 (en) New combination between 4-ä3-ÄCIS-hexahydrocyclopenta[C]pyrrol-2(1H)-YL]propoxyübenzamide and an NMDA receptor antagonist and pharmaceutical compositions containing it
PH12017501767A1 (en) Combination dosage form of a mu opioid receptor antagonist and an opioid agent
HK1197185A1 (en) Methods and compositions for treatment of epithelial wounds
IN2014DN09359A (enExample)
ES1073779Y (es) Barrera mixta, metal y madera, para carreteras.
HK1197536A (en) Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
HK1203373A1 (en) Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone